Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
45 hedge funds and large institutions have $39.5M invested in Dicerna Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 9 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
22% more capital invested
Capital invested by funds: $32.4M → $39.5M (+$7.09M)
10% less funds holding
Funds holding: 50 → 45 (-5)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.08M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$910K |
| 3 |
BlackRock
New York
|
+$361K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$282K |
| 5 |
6CM
683 Capital Management
New York
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
-$973K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$287K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$159K |
| 4 |
Millennium Management
New York
|
-$113K |
| 5 |
BCM
Bourgeon Capital Management
Darien,
Connecticut
|
-$85.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
51
A.R.T. Advisors
New York
| – | -$32K | -11,256 | Closed |
|
52
Barclays
London,
United Kingdom
| – | -$9.58K | -3,401 | -98% |
|
53
Bank of America
Charlotte,
North Carolina
| – | -$2.98K | -1,060 | -97% |
|
DRNA Hedge Fund Activity: Q1 2017 in Review
45 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2017, worth a combined $39.5M — up 22% from $32.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of DRNA and 8 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 15 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.08M. The largest seller was Abingworth, exiting entirely with an estimated $973K sold.
- 45 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2017, down from 50 in Q4 2016.
- Funds reported $39.5M of Dicerna Pharmaceuticals, Inc. stock for Q1 2017, up 22% quarter-over-quarter.
- 8 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2017 and 9 closed out, a net change of -1 holder.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2017 was EcoR1 Capital, an estimated $1.08M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2017 was Abingworth, an estimated $973K sold.
Based on aggregated 13F filings for Q1 2017.